key: cord-0721776-05kwcl94 authors: Murillo-Zamora, Efrén; Sánchez-Piña, Ramón Alberto; Trujillo, Xóchitl; Huerta, Miguel; Ríos-Silva, Mónica; Mendoza-Cano, Oliver title: Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults date: 2022-02-12 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.02.003 sha: 76d1c0876da15c767417b933cea7496ba8832e53 doc_id: 721776 cord_uid: 05kwcl94 Objective : To evaluate host factors associated with the risk of coronavirus disease 2019 (COVID-19) pneumonia in vaccinated adults. Methods : A cohort study was conducted in Mexico, and data from 1,607 adults with confirmed illness, with a positive history of COVID-19 vaccination, were analyzed. Risk ratios (RR) and 95% confidence intervals (CI) were computed as a measure of the significance of the associations between putative risk factors and the prevalence of COVID-19 pneumonia in vaccinated subjects. Results : The overall risk of pneumonia was 1.98 per 1,000 person-days. In the multiple regression analysis, older subjects and those with a history of smoking (current), obesity, and type 2 diabetes mellitus were at increased risk of pneumonia. Conclusions : Our results suggest that the effectiveness of COVID-19 vaccines may be reduced in a subset of adults who are elderly, or are smokers, obese or have type 2 diabetes mellitus. The availability of vaccines against coronavirus disease 2019 (COVID-19) represent a significant step towards ending the pandemic, and most COVID-19 vaccines confer close to 100% reduction in the risk of serious illness or death (Sharma et al. 2021) However, given that vaccine effectiveness may be affected by diverse factors that include host factors (such as age and comorbidities) and alignment of the vaccines with circulating strains, severe cases might still develop among fully vaccinated persons (Lopalco and DeStefano 2015) . This might be particularly relevant in the Mexico, where the pandemic burden has been high. The aim of this study was to evaluate the host factors that could be of use in predicting the risk of COVID-19 pneumonia in vaccinated adults. A nationwide retrospective cohort study was conducted in Mexico from August to October 2021, and a broader description of the research methods was previously published in a study evaluating predictors of COVID-19 pneumonia during the first semester of the pandemic (Murillo-Zamora et al. 2020) . Adults aged 20 years or older with laboratoryconfirmed (reverse-transcription polymerase chain reaction or rapid-antigenic test) disease, and illness onset from March to July 2021, and history of COVID-19 vaccination before illness onset, were extracted for this analysis. All subjects meeting the selection criteria were enrolled. The vaccinated subjects were those with two shots of any COVID-19 vaccine ( = 426; 26.5%) or a single-shot ( = 1,366; 73.5%) ≥ 1 f radiographic findings defined COVID-19 pneumonia (Government of Mexico, 2021), and factors associated with its risk were evaluated through risk ratios (RR), and 95% confidence intervals (CI) computed through generalized linear regression models. The Local Health Research Committee (601) of the Mexican Institute of Social Security approved this study (R-2020-601-015). Data from 1,607 patients were analyzed for a total follow-up of 21,713 person-days. The overall risk of pneumonia was 1.98 per 1,000 person-days (43/21,713), and the mortality in this group was 53.5% (23/43). When compared with patients without pneumonia, those with COVID-19 pneumonia were older (mean ± standard deviation, 65.5 ± 12.0 vs. 49.5 ± 14.4 years old, < 0.001) and had a higher prevalence of chronic non-communicable conditions ( Figure 1) . A broader description of the study sample is presented as Supplementary data 1. In multiple regression analysis ( pneumonia. Our results suggest that the effectiveness of COVID-19 vaccines in preventing severe illness may be diminished by host characteristics, including age and conditions associated with unhealthy lifestyles (namely smoking, obesity, and type 2 diabetes mellitus). The elderly is at risk of a progressive decline in function of the immune system, called immunosenescence, that could be associated with diminished humoral and cellular immune responses (Nikolich-Ž h 2018). In our study, the risk of COVID-19 pneumonia increased an average of 0.2% (RR per year = 1.002, 95% CI 1.001-1.003) per year of age. Therefore, and even if fully vaccinated, older adults are at increased risk of serious illness, and other protective measures should be taken to reduce the risk of infection. The prevalence of smoking among the patients with pneumonia was higher than among non-severe COVID-19 cases (30.2% vs 7.0%; RR = 1.07, 95% CI 1.04-1.10). The prevalence among all those with COVID-19 infection was also higher than the general prevalence of smokers among Mexican adults aged 20 years or older (National Institute of Public Health of Mexico, Health and Nutrition Survey 2018; 30.5% vs.11.4%). The differences are not unexpected given that smoking history has been associated with a poorer COVID-19 outcome (Zhao et al. 2020) . Published data also suggest reduced effectiveness of influenza vaccine among smokers (Godoy et al. 2018) . We also observed a significant increase in the risk of pneumonia in vaccinated adults with type 2 diabetes mellitus (RR = 1.03, 95% CI 1.01-1.05) and obesity (RR = 1.02, 95% CI 1.01-1.04). Both conditions have also been associated with poor disease outcomes among unvaccinated patients in other populations (Zhou et al., 2021) as well as in Mexico (Barquera and Rivera, 2020) . Finally, and according to the aim of our study, we clustered the vaccinated participants and no specific estimates (RR) were obtained for each of the received vaccines. As presented in Supplementary data 1, the AZD1222 Covishield (AstraZeneca) or BNT162b2 (Pfizer, Inc./BioNTech) vaccine were administered in most (82%) of enrolled subjects. The effectiveness of COVID-19 vaccines may be reduced in a subset of adults who are elderly, or are smokers, obese or have type 2 diabetes mellitus. EMZ performed the experiments, analyzed the data and also wrote the first draft of the manuscript; XT made data analysis and data collection, RASP and MH contributed with the Methodology and Writing-review and editing; MRS contributed with revisions and data analysis and OMC conceived and designed the experiments, and also is responsible for the final version of the manuscript, that has been read and approved by all authors. This research received no external funding. All data generated or analyzed during this study are included in this published article. The Local Health Research Committee approved this study of the IMSS (approval R-2020-601-015). Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly Clinical guidelines for the treatment of COVID-19 in Mexico: Inter-institutional consensus The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease Online document in Spanish] Nikolich-Ž h J h w h f : p f h system Vaccines for COVID-19: Where do we stand in 2021? The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19) None declared under financial, general, and institutional competing interests.